Single-arm tumor-agnostic study | Avelumab plus Talazoparib in patients with BRCA1/2- or ATM-Altered advanced solid tumors. 21 Nov, 2022 | 14:07h | UTC Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial – JAMA Oncology